Thymosin alpha-1 reduces infections 44%, boosts immune cells, and improves outcomes in severe pancreatitis | Research

The takeaway

Meta-analysis of 5 RCTs (706 patients) shows thymosin alpha-1 in severe acute pancreatitis increased CD4+ T cells, improved CD4/CD8 ratio, reduced extrapancreatic infections by 44% (especially blood and abdominal), and lowered APACHE II scores.

44% fewer infections
Thymosin alpha-1 reduced extrapancreatic infections by 44% in severe acute pancreatitis by restoring CD4+ T cell balance—a life-saving immune intervention

What the researchers found

↑CD4+ T cells (MD=4.53, p<0.00001). ↑CD4/CD8 ratio (MD=0.42, p<0.00001). ↓CRP (low-dose): -30 mg/L (p<0.00001). ↓Infections: RR 0.56 (p=0.0005). Blood: RR 0.60. Abdominal: RR 0.38. ↓APACHE II: -1.52 (p<0.0001). Hospital stay: NS. 5 RCTs, 706 patients.

Why it matters

SAP has 20-40% mortality, largely from secondary infections due to immune suppression. Tα1's ability to restore immune function and prevent infections addresses a critical unmet need.

How the study worked

Meta-analysis of 5 RCTs from PubMed, Embase, WoS, Cochrane, CNKI. 706 SAP patients. Review Manager 5.3. Random/fixed effects. PROSPERO CRD42024570517.

What this study cannot tell us

Only 5 RCTs available. Mostly Chinese studies. High-dose Tα1 did not reduce CRP (dose-response paradox). Hospital stay not reduced. Lung infection reduction NS.

How to read the evidence

Meta-analysis of 5 RCTs with 706 patients. Moderate evidence quality.

When this study was published

Published in 2025.

The bigger picture

Tα1 is one of the few peptide immunomodulators with proven efficacy in critical care. Its ability to reverse SAP immune suppression and prevent lethal infections positions it as a standard of care candidate for severe pancreatitis.

Questions still open

What is the optimal Tα1 dose for SAP?
Should Tα1 be routine in ICU SAP management?
Why did higher doses show less anti-inflammatory effect?

Common questions

What is thymosin alpha-1 used for in critical care?

Tα1 is an immune-boosting peptide that restores immune function in critically ill patients whose immune systems are suppressed. In severe pancreatitis, it increased protective immune cells (CD4+ T cells) and reduced dangerous secondary infections by 44%—especially bloodstream and abdominal infections.

Does thymosin alpha-1 help pancreatitis patients survive?

It helps by preventing the infections that kill pancreatitis patients. While it did not reduce hospital stay in this analysis, it significantly reduced infections (44% less) and improved disease severity scores. Blood infections dropped 40% and abdominal infections 62%—potentially life-saving in severe cases.

Read the original research

Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.

Frontiers in immunology, 16, 1571456

View on PubMed ↗Publisher’s paper ↗

Citation

Tian, Yong; Yao, Jiaqi; Ma, Yihan; Zhang, Pengcheng; Zhou, Xiaofang; Xie, Wenjie; Tang, Wenfu. (2025). Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.. Frontiers in immunology, 16, 1571456. https://doi.org/10.3389/fimmu.2025.1571456